EICHORPublic-registry site landscape for NCT04226170, “Study of Pyridostigmine With Ondansetron in Subjects With Anti-AchR Positive Myasthenia Gravis”, a Myasthenia Gravis study sponsored by DAS-MG, Inc. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT04226170 (registry record) |
| Study title | Study of Pyridostigmine With Ondansetron in Subjects With Anti-AchR Positive Myasthenia Gravis |
| Official title | A Phase II, Study to Evaluate the Safety and Tolerability of Pyridostigmine When Given With Ondansetron to Subjects With Anti-AchR Positive Myasthenia Gravis |
| Sponsor | DAS-MG, Inc |
| Condition(s) | Myasthenia Gravis |
| Phase | PHASE2 |
| Listed sites | 1 |
| Site countries | United States |
Patient-friendly overview of this study: eichor.com/study/NCT04226170.
Eichor generates a preliminary site-risk snapshot for NCT04226170 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
Other Myasthenia Gravis trials
← Eichor home · All tracked trials · Myasthenia Gravis studies · Weekly briefs
